מדינה: אוסטרליה
שפה: אנגלית
מקור: Department of Health (Therapeutic Goods Administration)
dipyridamole
Boehringer Ingelheim Pty Ltd
Registered
PERSANTIN ® SR 200 MG _SUSTAINED RELEASE CAPSULES_ _dipyridamole_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Persantin SR. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking Persantin SR against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. This leaflet was last updated on the date at the end of this leaflet. More recent information may be available. The latest Consumer Medicine Information is available from your pharmacist, doctor, or from www.medicines.org.au and may contain important information about the medicine and its use of which you should be aware. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT PERSANTIN SR IS USED FOR Persantin SR contains dipyridamole. It is used to help prevent the recurrence of stroke in people who have had a previous stroke or transient ischaemic attack (TIA). This type of medication is called an anticoagulant. Some people refer to anticoagulant medicines as “blood thinners”. Dipyridamole works by preventing blood clots from forming. It works on the blood cells that help blood to clot (platelets) and prevents them from clumping and sticking together. This reduces the risk of forming blood clots that can lead to a stroke. Dipyridamole also widens the blood vessels of the heart. Persantin SR is prescribed either alone or in conjunction with aspirin. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another reason. BEFORE YOU TAKE PERSANTIN SR _WHEN YOU MUST NOT TAKE IT_ DO NOT TAKE PERSANTIN SR IF YOU HAVE AN ALLERGY TO: • any medicine containing dipyridamole • any of the ingredients listed at the end of this leaflet. Some of the symptoms of an allergic reaction may includ קרא את המסמך השלם
PERSANTIN SR PI0061-08 1 AUSTRALIAN PRODUCT INFORMATION – PERSANTIN SR (DIPYRIDAMOLE) SUSTAINED- RELEASE CAPSULES 1 NAME OF THE MEDICINE dipyridamole 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM Each PERSANTIN SR 200 mg sustained-release capsule contains dipyridamole 200 mg. The gelatin shell of the capsule consists of a red opaque cap and an orange opaque body. For the full list of excipients, see Section 6.1 List of excipients. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS PERSANTIN SR 200 mg sustained-release capsules are indicated for the secondary prevention of ischaemic stroke and transient ischaemic attacks in conjunction with low-dose aspirin. PERSANTIN SR can be used alone if aspirin is not tolerated. 4.2 DOSE AND METHOD OF ADMINISTRATION The recommended dose is one capsule twice daily, usually one in the morning and one in the evening, preferably with food. The capsules should be swallowed whole without chewing. 4.3 CONTRAINDICATIONS Hypersensitivity to dipyridamole or to any excipients in the product. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE CARDIOVASCULAR DISORDERS Because PERSANTIN SR is a potent vasodilator, it should be used with caution in patients with severe coronary artery disease (e.g. unstable angina or recently sustained myocardial infarction), subvalvular aortic stenosis, or haemodynamic instability (e.g. decompensated heart failure). STRESS TESTING WITH INTRAVENOUS DIPYRIDAMOLE AND OTHER ADENOSINERGIC AGENTS Patients treated with regular oral doses of PERSANTIN SR should not receive additional intravenous dipyridamole. If pharmacological stress testing with intravenous dipyridamole or other adenosinergic agents (e.g. adenosine, regadenoson) is considered necessary, drugs containing oral dipyridamole (e.g. ASASANTIN SR, PERSANTIN) should be interrupted for 24 hours prior to administration of intravenous dipyridamole or 48 hours prior to administration of other adenosinergic agents because the risk of cardiovascular side effects may increase. Intake of קרא את המסמך השלם